KEYNOTE-024
This is a phase III trial pitting pembrolizumab against investigator’s choice of five platinum-based chemotherapeutic regimens in treatment-naïve metastatic non-small-cell lung cancer patients with at least 50% PD-L1-positive tumor cells.
Results
The primary analysis and 2-year update both showed that patients derive a significant survival benefit from treatment with pembrolizumab versus chemotherapy.
The three-year results from the KEYNOTE-024 trial point to the durable efficacy of pembrolizumab monotherapy in this setting.
IMpower131
This phase III study has previously shown significantly improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab to chemotherapy for stage IV squamous non-small-cell lung cancer, but has failed to demonstrate an overall survival (OS) advantage thus far.
Results
The final analysis of the IMpower131 trial revealed an OS benefit with the addition of atezolizumab to carboplatin and nab-paclitaxel chemotherapy for treatment-naïve patients with stage IV squamous NSCLC who strongly express PD-L1.
The final OS analysis was reported at WCLC 2019:
Title: IMpower131: Final OS results of carboplatin + nab-paclitaxel ± atezolizumab in advanced squamous NSCLC
Presenter: Federico Cappuzzo, AUSL Romagna, Ravenna, Italy
Tuesday, September 10: 11:40–11:50 (Abstract OA14.02)
CheckMate 017 and 057
CheckMate 017 and 057 are phase III trials of nivolumab versus docetaxel in previously treated patients with stage IIIB/IV squamous and nonsquamous non-small-cell lung cancer, respectively. Positive results favoring the PD-1 inhibitor have been published for each trial, with the most recent being a pooled analysis of the 3-year outcomes.
The trial investigators presented the 5-year results from the two trials at WCLC 2019:
Title: Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: Nivolumab vs docetaxel in previously treated NSCLC
Presenter: Scott Gettinger, Yale School of Medicine, New Haven, Connecticut, USA
Tuesday, September 10: 12:00–12:10 (Abstract OA14.04)